Two Sigma Advisers’s Flexion Therapeutics, Inc. FLXN Stock Holding History

Two Sigma Advisers’s Portfolio FLXN Stock Details FLXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-457,744	Closed	-$2.79M	–	2883
2021 Q3	$2.79M	Sell	457,744 -286,400	-38%	-$1.79M	0.01%	1073
2021 Q2	$6.12M	Sell	744,144 -51,500	-6%	-$438K	0.02%	768
2021 Q1	$7.12M	Buy	795,644 +635,300	+396%	+$7.28M	0.02%	706
2020 Q4	$1.85M	Buy	160,344 +2,800	+2%	+$32.5K	﹤0.01%	1308
2020 Q3	$1.64M	Buy	157,544 +65,900	+72%	+$808K	﹤0.01%	1270
2020 Q2	$1.21M	Buy	91,644 +49,000	+115%	+$508K	﹤0.01%	1488
2020 Q1	$336K	Buy	42,644 +32,444	+318%	+$489K	﹤0.01%	1969
2019 Q4	$211K	Buy	+10,200	New	+$172K	﹤0.01%	2169

Two Sigma Advisers's FLXN Position: Q4 2021 in Review

Two Sigma Advisers sold out of Flexion Therapeutics, Inc. (FLXN) in Q4 2021, closing a stake of 457,744 shares — an estimated $2.79M sold.

Two Sigma Advisers first reported a position in FLXN in Q4 2019 and held it in 8 quarters. The position peaked at $7.12M in Q1 2021. 1 fund tracked by Wall St. Rank holds FLXN as of Q4 2021.

Two Sigma Advisers reported no remaining Flexion Therapeutics, Inc. position as of Q4 2021 after selling out during the quarter.
Two Sigma Advisers sold 457,744 Flexion Therapeutics, Inc. shares in Q4 2021, an estimated $2.79M.
Two Sigma Advisers first reported a position in Flexion Therapeutics, Inc. in Q4 2019 and held it in 8 quarters.
Two Sigma Advisers's Flexion Therapeutics, Inc. position peaked at $7.12M in Q1 2021.
1 fund tracked by Wall St. Rank held Flexion Therapeutics, Inc. as of Q4 2021.

Based on Two Sigma Advisers's 13F filing for Q4 2021, filed 14 Feb 2022.